In an attempt to right course on the experimental blood thinner tecarfarin, ARYx Therape tics said this morning that the FDA had confirmed it is on the right development path for a regulatory approval. The oral drug failed a Phase II/III trial last summer, triggering a sharp drop in the company's stock price. The FDA said that an additional trial that compares the experimental therapy with warfarin in a real-world setting could be used to obtain an approval. "We anticipate continuing this dialogue with the FDA as we now seek their approval for the specific design of the real-world trial through a Special Protocol Assessment," Chief Executive Paul Goddard said in a statement. Report